News

Active Biotech has achieved primary end point in ongoing Phase II clinical trial of TASQ, in patients with asymptomatic, castrate resistant, metastatic prostate cancer. The first analysis of

Intercell and GlaxoSmithKline Biologicals (GSK) will form a strategic alliance to accelerate the development and commercialisation of needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine for

Sanofi-aventis has launched its new production units at the Le Trait site in a ceremony attended by Jean-Marie Aline, Mayor of Le Trait, Christophe Bouillon, Member of the

Takeda and Pronova BioPharma have announced that the advancement of TAK-085 (omega-3 acid ethyl esters 90) for the treatment of hypertriglyceridemia into Phase 3 clinical programs in Japan.

Evotec has received a milestone payment from Ono Pharmaceutical (Ono) from its research collaboration aimed at identifying inhibitors for a protease target. The milestone is received for the

Ipsen reports the preliminary results of a Phase I trial in metastatic breast cancer with BN83495, first-in-class orally available irreversible steroid sulfatase (STS) inhibitor. In the course of

Basilea Pharmaceutica has announced that Toctino (alitretinoin) was recommended for regulatory approval under the repeat-use procedure in 13 additional EU Member States as well as in Norway and

Abbott has entered into a definitive agreement to acquire Starlims Technologies for approximately $123m in cash. As Abbott integrates Starlims into its existing portfolio of laboratory information management

FDA has granted Emergency Use Authorization (EUA) for DxNA’s 2009 H1N1 influenza virus diagnostic test for use in its GeneSTAT detection platform. The new platform enables fast detection